Removable Titanium Clip Treatment for Acute Variceal Hemorrhage from the Gastric Fundus
Launched by SHUPEI LI · Dec 12, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new treatment method using removable titanium clips for patients experiencing acute bleeding from swollen blood vessels in the stomach, known as gastric variceal bleeding. The aim is to see if this treatment can help control the bleeding and improve patient outcomes. The trial is currently recruiting participants aged 18 to 75 who have been diagnosed with cirrhosis, have experienced symptoms of upper gastrointestinal bleeding, and have been confirmed to have bleeding from gastric varices during an endoscopy.
To be eligible for this trial, participants must agree to take part and sign an informed consent form. They should be stable in terms of their health before or after receiving initial fluid treatment. However, individuals with certain conditions, such as bleeding from other areas, serious heart or lung diseases, or those who are pregnant or breastfeeding, cannot participate. If you or a loved one meets these criteria and are interested in learning more about this trial, you can expect to receive close monitoring and care during the study to help manage the bleeding effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The patient and their family agree to and sign the relevant informed consent form.
- • 2. Diagnosed with cirrhosis based on clinical manifestations, laboratory tests, imaging findings, or pathological examinations.
- • 3. History of symptoms related to variceal upper gastrointestinal bleeding, such as hematemesis, melena, or rectal bleeding.
- • 4. Patients confirmed by endoscopy to have bleeding from ruptured gastric varices.
- • 5. Patients who are hemodynamically stable before or after initial fluid resuscitation.
- • 6. Aged 18 to 75 years.
- Exclusion Criteria:
- • 1. Those with concomitant bleeding from ruptured esophageal varices.
- • 2. A history of gastrointestinal-related surgical procedures.
- • 3. Individuals with altered consciousness who are difficult to treat.
- • 4. Those with concomitant malignant tumors.
- • 5. Individuals with serious diseases involving the heart, brain, lungs, or kidneys.
- • 6. Pregnant and breastfeeding women.
- • 7. Those with contraindications to relevant treatments.
About Shupei Li
Shupei Li is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes through rigorous scientific investigation, Shupei Li collaborates with healthcare professionals and research institutions to design and implement clinical trials that adhere to the highest ethical and regulatory standards. Their expertise spans a range of therapeutic areas, enabling them to contribute to the development of novel treatments and therapies that address critical health needs. Through a patient-centered approach, Shupei Li strives to ensure that all clinical trials prioritize safety, efficacy, and the well-being of participants, ultimately aiming to bring transformative solutions to market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported